BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 29, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Cervarix: Phase III data

A double-blind, Costa Rican Phase III trial in 4,210 evaluable women aged 18-25 showed that Cervarix led to a lower prevalence of anal HPV 16/18 infection vs. a modified formulation of Havrix hepatitis A virus vaccine at 4 years post-vaccination (2.2% vs. 5.9%). Cervarix also led to a lower prevalence of infection with HPV 16/18 at the cervix vs. control at 4 years post-vaccination...

Read the full 309 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >